George Garratty

American Red Cross Blood Services, United States of America

George Garratty, MD, PhD

Academic positions:
- Scientific Director, American Red Cross Blood Services, Los Angeles
- Clinical Professor of Pathology at the University of California, Los Angeles

All industry positions (in last five years):
None declared

Research interests:

Any other information:
Dr Garratty has been on several national committees, including the Standards Committee of the American Association of Blood Banks, and is an Associate Editor of Transfusion.. He has also represented North America on the International Society of Blood Transfusion Council.

He has received several prestigious awards, including the Ivor Dunsford (1978), Emily Cooley (1989), and Morten Grove-Rasmussen (1994) Memorial Awards of the American Association of Blood Banks; the Charles R. Drew Award of the American Red Cross (1987); and the Owen Thomas Memorial Award of the California blood Bank System (1987); and the Outstanding Research Award of the American Society of Clinical Pathologists (1998).

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Hematology > Anemias & Hypocellular Marrow Disorders (since 03 February 2006)

Links

http://chapters.redcross.org/ca/socal/research/garratty.html

All recent recommendations

• 3.2
  The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia.
  Recommended by Greg Bociek, George Garratty
  
• 3.0
  Lack of Duffy antigen expression is associated with organ damage in patients with sickle cell disease.
  Recommended by George Garratty
  
• 3.0
  Does an alloimmune response to strong immunogenic red blood cell antigens enhance a response to weaker antigens?
  Recommended by George Garratty
  
• 3.0
  A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor.
  Recommended by George Garratty
  
• 3.0
  Mannose-binding lectin is involved in multiple organ dysfunction syndrome after cardiac surgery: effects of blood transfusions.
  Recommended by George Garratty
  
• 3.0
  Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia.
  Recommended by George Garratty
  
• 3.0
  S-nitrosohemoglobin deficiency: a mechanism for loss of physiological activity in banked blood.
  Recommended by George Garratty
  
• 3.0
  Platelet and red blood cell phagocytosis kinetics are differentially controlled by phosphatase activity within mononuclear cells.
  Recommended by George Garratty
  
• 6.0
  Deletion of the dominant autoantigen in NZB mice with autoimmune hemolytic anemia: effects on autoantibody and T-helper responses.
  Recommended by George Garratty
  
• 3.0
  Coexistence of autoantibodies and alloantibodies to red blood cells due to blood transfusion.
  Recommended by George Garratty
  
• 3.0
  Mapping helper T-cell epitopes on platelet membrane glycoprotein IIIa in chronic autoimmune thrombocytopenic purpura.
  Recommended by George Garratty
  
• 3.0
  Patients with quinine-induced immune thrombocytopenia have both "drug-dependent" and "drug-specific" antibodies.
  Recommended by George Garratty
  
• 3.0
  Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.
  Recommended by George Garratty
  
• 3.0
  Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy.
  Recommended by George Garratty
  
• 3.0
  Unavailability of CD147 leads to selective erythrocyte trapping in the spleen.
  Recommended by George Garratty
  
• 3.0
  Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.
  Recommended by George Garratty
  
• 6.0
  Immune responses and tolerance to the RhD blood group protein in HLA-transgenic mice.
  Recommended by George Garratty
  
• 3.0
  Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change.
  Recommended by George Garratty